Literature DB >> 25480415

Role of 5-hydroxymethylcytosine level in diagnosis and prognosis prediction of intrahepatic cholangiocarcinoma.

Zhao-Ru Dong1, Chi Zhang, Jia-Bin Cai, Peng-Fei Zhang, Guo-Ming Shi, Dong-Mei Gao, Hui-Chuan Sun, Shuang-Jian Qiu, Jian Zhou, Ai-Wu Ke, Jia Fan.   

Abstract

The loss of 5-hydroxymethylcytosine (5-hmC) has been identified as an epigenetic hallmark in several malignancies. However, its role in intrahepatic cholangiocarcinoma (ICC) is still unknown. Our study aims to investigate the level of 5-hmC in diagnosis and prognosis prediction of ICC. The 5-hmC levels were detected using dot blot, tissue microarray technique and immunohistochemical method, and the correlation between 5-hmC level and ICC clinicopathological parameters was analysed. Compared with matched liver tissues, most of ICC tissues presented with the loss of 5-hmC. Furthermore, the subgroups of cirrhotic and poor differentiation tissues showed the lowest level of 5-hmC. We found that 5-hmC level in non-elevated ICC patients was significantly related to lymph node metastasis and TNM stage and not related to vessel invasion, sex, age, HBV, cirrhosis or degree of differentiation. ICC patients with high TNM stage (stages III and IV) and lymph node metastases had significantly lower 5-hmC level than those with low TNM stage (stages I and II) and no lymph node metastases. Further analysis showed that low 5-hmC level is significantly correlated with worse overall survival (OS) and disease-free survival (DFS). Importantly, multivariate analysis indicated that 5-hmC level, tumour diameter, lymphatic metastasis and tumour differentiation could be used as independent prognostic factors for ICC. The loss of 5-hmC is implicated in the progression of ICC. Our results can contribute to the diagnostic ability and postoperative surveillance of ICC patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25480415     DOI: 10.1007/s13277-014-2900-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  28 in total

1.  Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival.

Authors:  Giorgio Ercolani; Gaetano Vetrone; Gian Luca Grazi; Osamu Aramaki; Matteo Cescon; Matteo Ravaioli; Carla Serra; Giovanni Brandi; Antonio Daniele Pinna
Journal:  Ann Surg       Date:  2010-07       Impact factor: 12.969

Review 2.  Intrahepatic cholangiocarcinoma: a malignancy of increasing importance.

Authors:  Chet W Hammill; Linda L Wong
Journal:  J Am Coll Surg       Date:  2008-06-02       Impact factor: 6.113

3.  The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.

Authors:  Rasheduzzaman Chowdhury; Kar Kheng Yeoh; Ya-Min Tian; Lars Hillringhaus; Eleanor A Bagg; Nathan R Rose; Ivanhoe K H Leung; Xuan S Li; Esther C Y Woon; Ming Yang; Michael A McDonough; Oliver N King; Ian J Clifton; Robert J Klose; Timothy D W Claridge; Peter J Ratcliffe; Christopher J Schofield; Akane Kawamura
Journal:  EMBO Rep       Date:  2011-04-01       Impact factor: 8.807

Review 4.  Risk factors for cholangiocarcinoma.

Authors:  Gia L Tyson; Hashem B El-Serag
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

5.  Prognostic value of cirrhosis for intrahepatic cholangiocarcinoma after surgical treatment.

Authors:  Ya-yong Li; Hao Li; Pin Lv; Gang Liu; Xiao-rong Li; Bu-ning Tian; Dao-jin Chen
Journal:  J Gastrointest Surg       Date:  2011-01-19       Impact factor: 3.452

Review 6.  IDH mutations in glioma and acute myeloid leukemia.

Authors:  Lenny Dang; Shengfang Jin; Shinsan M Su
Journal:  Trends Mol Med       Date:  2010-08-05       Impact factor: 11.951

7.  Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients.

Authors:  Qi Yang; Kexia Wu; Meiju Ji; Weilin Jin; Nongyue He; Bingyin Shi; Peng Hou
Journal:  J Biomed Nanotechnol       Date:  2013-09       Impact factor: 4.099

Review 8.  Pathogenesis, diagnosis, and management of cholangiocarcinoma.

Authors:  Sumera Rizvi; Gregory J Gores
Journal:  Gastroenterology       Date:  2013-10-15       Impact factor: 22.682

9.  Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.

Authors:  P Wang; Q Dong; C Zhang; P-F Kuan; Y Liu; W R Jeck; J B Andersen; W Jiang; G L Savich; T-X Tan; J T Auman; J M Hoskins; A D Misher; C D Moser; S M Yourstone; J W Kim; K Cibulskis; G Getz; H V Hunt; S S Thorgeirsson; L R Roberts; D Ye; K-L Guan; Y Xiong; L-X Qin; D Y Chiang
Journal:  Oncogene       Date:  2012-07-23       Impact factor: 8.756

10.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

View more
  13 in total

1.  Correlation between metastatic lymph node ratio and prognosis in patients with extrahepatic cholangiocarcinoma.

Authors:  Jian-Wei Zhang; Yun-Mian Chu; Zhong-Min Lan; Xiao-Long Tang; Ying-Tai Chen; Cheng-Feng Wang; Xu Che
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

Review 2.  Ten-eleven translocase: key regulator of the methylation landscape in cancer.

Authors:  Jyoti Shekhawat; Kavya Gauba; Shruti Gupta; Bikram Choudhury; Purvi Purohit; Praveen Sharma; Mithu Banerjee
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-28       Impact factor: 4.553

3.  Reduced hydroxymethylation characterizes medulloblastoma while TET and IDH genes are differentially expressed within molecular subgroups.

Authors:  Karina Bezerra Salomão; Gustavo Alencastro Veiga Cruzeiro; Ricardo Bonfim-Silva; Lenisa Geron; Fernando Ramalho; Fabiano Pinto Saggioro; Luciano Neder Serafini; Daniel Antunes Moreno; Rosane Gomes de Paula Queiroz; Simone Dos Santos Aguiar; Izilda Cardinalli; José Andres Yunes; Silvia Regina Brandalise; Maria Sol Brassesco; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  J Neurooncol       Date:  2018-03-26       Impact factor: 4.130

4.  Low level of 5-Hydroxymethylcytosine predicts poor prognosis in non-small cell lung cancer.

Authors:  Yunfei Liao; Jie Gu; Yongbing Wu; Xiang Long; D I Ge; Jianjun Xu; Jianyong Ding
Journal:  Oncol Lett       Date:  2016-04-19       Impact factor: 2.967

5.  CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity.

Authors:  Zhao-Ru Dong; Ai-Wu Ke; Tao Li; Jia-Bing Cai; Ya-Fei Yang; Wei Zhou; Guo-Ming Shi; Jia Fan
Journal:  Mol Cancer       Date:  2021-05-13       Impact factor: 27.401

6.  TET family proteins and 5-hydroxymethylcytosine in esophageal squamous cell carcinoma.

Authors:  Asuka Murata; Yoshifumi Baba; Takatsugu Ishimoto; Keisuke Miyake; Keisuke Kosumi; Kazuto Harada; Junji Kurashige; Shiro Iwagami; Yasuo Sakamoto; Yuji Miyamoto; Naoya Yoshida; Manabu Yamamoto; Shinya Oda; Masayuki Watanabe; Mitsuyoshi Nakao; Hideo Baba
Journal:  Oncotarget       Date:  2015-09-15

Review 7.  Decreased 5-hydroxymethylcytosine levels correlate with cancer progression and poor survival: a systematic review and meta-analysis.

Authors:  Zhaoli Chen; Xuejiao Shi; Lanwei Guo; Yuan Li; Mei Luo; Jie He
Journal:  Oncotarget       Date:  2017-01-03

8.  Combined preoperative albumin-bilirubin (ALBI) and serum γ-glutamyl transpeptidase (GGT) predicts the outcome of hepatocellular carcinoma patients following hepatic resection.

Authors:  Chi-Hao Zhang; Xiao-Chun Ni; Bi-Yin Chen; Shuang-Jian Qiu; Yi-Ming Zhu; Meng Luo
Journal:  J Cancer       Date:  2019-08-27       Impact factor: 4.207

Review 9.  The role of microRNAs in intrahepatic cholangiocarcinoma.

Authors:  Zheng Li; Jianxiong Shen; Matthew T V Chan; William Ka Kei Wu
Journal:  J Cell Mol Med       Date:  2016-09-13       Impact factor: 5.310

10.  Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis.

Authors:  Zhao-Ru Dong; Jie Zou; Dong Sun; Guo-Ming Shi; Ai-Wu Ke; Jia-Bin Cai; Hui-Chuan Sun; Shuang-Jian Qiu; Tao Li; Jian Zhou; Xu-Ting Zhi; Jia Fan
Journal:  J Cancer       Date:  2017-10-17       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.